Citation: | ZHU Miao, ZHANG Jing, GENG Ping, WANG Jing, LIU Yanqing, CAO Liuzhao, LI Tiantian, SUN Mei. Analysis in early clinical characteristics of Coronavirus Disease 2019 patients with Delta strain in Yangzhou City of Jiangsu Province[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 4-8. DOI: 10.7619/jcmp.20213956 |
[1] |
World Health Organization. WHO Coronavirus (COVID-19) Dashboard[EB/OL]. (2021-10-07)[2021-10-07].
https://covid19.who.int/.
|
[2] |
PéREZ-ABELEDO M, SANZ MORENO J C. SARS-CoV-2 variants, a still unfinished story[J]. Vacunas, 2021, 22(3): 173-179. doi: 10.1016/j.vacun.2021.06.003
|
[3] |
中华人民共和国卫生健康委员会办公厅. 新型冠状病毒肺炎防控方案(第七版)[EB/OL]. (2020-09-15)[2021-03-11].
http://www.nhc.gov.cn/jkj/s3577/202009/318683cbfaee4191aee29cd774b19d8d.shtml.
|
[4] |
中华人民共和国卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第八版)[EB/OL]. (2020-08-18)[2021-03-11].
http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml.
|
[5] |
HASSAN S A, SHEIKH F N, JAMAL S, et al. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment[J]. Cureus, 2020, 12(3): e7355. http://www.researchgate.net/publication/340923805_Coronavirus_COVID-19_A_Review_of_Clinical_Features_Diagnosis_and_Treatment
|
[6] |
CASCELLA M, RAJNIK M, ALEEM A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19)[EB/OL]. (2021-01-30)[2021-07-30].
https://pubmed.ncbi.nlm.nih.gov/32150360/.
|
[7] |
KANNAN S R, SPRATT A N, COHEN A R, et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses[J]. J Autoimmun, 2021, 124: 102715. doi: 10.1016/j.jaut.2021.102715
|
[8] |
张文婷, 钟文芳, 杨佩, 等. 广州市新型冠状病毒肺炎病例密切接触者核酸检测灵敏度和特异度分析[J]. 中华流行病学杂志, 2021, 42(8): 1347-1352.
|
[9] |
关明, 王文静, 王惠英. 新型冠状病毒无症状感染者的实验室检测及防控风险评估[J]. 中华预防医学杂志, 2020, 54(12): 1310-1314. doi: 10.3760/cma.j.cn112150-20200610-00861
|
[10] |
HODGSON S H, MANSATTA K, MALLETT G, et al. What defines an efficacious COVID-19 vaccine A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2[J]. Lancet Infect Dis, 2021, 21(2): e26-e35. doi: 10.1016/S1473-3099(20)30773-8
|
[11] |
PRITCHARD E, MATTHEWS P C, STOESSER N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom[J]. Nat Med, 2021, 27(8): 1370-1378. doi: 10.1038/s41591-021-01410-w
|
[12] |
DAGAN N, BARDA N, KEPTEN E, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting[J]. N Engl J Med, 2021, 384(15): 1412-1423. doi: 10.1056/NEJMoa2101765
|
[13] |
朱淼, 吕清泉, 顾明华, 等. 江苏省扬州地区确诊新型冠状病毒肺炎患者的中西医结合临床诊治和效果评价[J]. 实用临床医药杂志, 2020, 24(5): 1-5. doi: 10.7619/jcmp.202005001
|
[14] |
CHAI J, CAI Y, PANG C, et al. Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1[J]. Nat Commun, 2021, 12(1): 3433. doi: 10.1038/s41467-021-23533-x
|
[15] |
GRANT R A, MORALES-NEBREDA L, MARKOV N S, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia[J]. Nature, 2021, 590(7847): 635-641. doi: 10.1038/s41586-020-03148-w
|
[16] |
ZUBAIR A S, MCALPINE L S, GARDIN T, et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019[J]. JAMA Neurol, 2020, 77(8): 1018. doi: 10.1001/jamaneurol.2020.2065
|
[17] |
TAN L, WANG Q, ZHANG D Y, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study[J]. Signal Transduct Target Ther, 2020, 5(1): 1-3. doi: 10.1038/s41392-019-0089-y
|
[18] |
MANNE B K, DENORME F, MIDDLETON E A, et al. Platelet gene expression and function in patients with COVID-19[J]. Blood, 2020, 136(11): 1317-1329. doi: 10.1182/blood.2020007214
|